GENERAL ANTIBIOTIC RECOMMENDATIONS FOR COMMON INFECTIONS
|
|||
Infection Type |
Most Common Organism |
Other Considerations |
Initial Antibiotic Therapy |
Cellulitis |
Staphylococcus Streptococcus |
Antibiotic synergy for streptococcal infections with clindamycin |
First-generation cephalosporin or penicillin (Streptococcus only) |
Abscess (e.g., paronychia, felon, deep space infections) |
Staphylococcus aureus |
MRSA is common now in the community; start therapy for MRSA empirically and change to nafcillin or first-generation cephalosporin if methicillin sensitive |
IV: Vancomycin or clindamycin for inpatients Linezolid or tigecycline if unable to tolerate vancomycin Oral: Trimethoprim/sulfamethoxazole (Bactrim), clindamycin or doxycycline |
|
|
|
|
Flexor tenosynovitis |
Staphylococcus aureus, anaerobes |
Polymicrobial infections have worse prognosis. Consider multimodal therapy as initial treatment until culture results are back, especially in immunocompromised patients |
IV: Ampicillin/sulbactam (Unasyn) plus cefoxitin (second-generation cephalosporin) Oral: Amoxicillin/clavulanate (Augmentin) If penicillin allergic: fluoroquinolone (Cipro or other) plus clindamycin |
|
|
|
|
Pyarthrosis |
Staphylococcus |
Requires parenteral therapy MRSA is common now in the community; start therapy for MRSA empirically and change to nafcillin or first-generation cephalosporin if methicillin-sensitive Consider coverage for Neisseria gonorrhoeae in sexually active patients |
IV: Vancomycin Add ceftriaxone for N. gonorrhoeae coverage Presumptive treatment for MRSA until cultures are back, then change to antibiotic appropriate to organism with the least side-effect profile |
|
|
|
|
Human bite |
Staphylococcus Streptococcus Eikenella corrodens Anaerobes |
|
IV: Ampicillin/sulbactam (Unasyn) plus cefoxitin Oral: Amoxicillin/clavulanate (Augmentin) If penicillin allergic: fluoroquinolone (Cipro) plus clindamycin Alternative: Third-generation cephalosporin plus anerobic coverage with clindamycin or metronidazole (Flagyl) Note: Quinolones not indicated in children |
|
|
|
|
Animal bites |
Pasteurella multocida Staphylococcus Streptococcus |
|
IV: Ampicillin/sulbactam (Unasyn) plus cefoxitin Oral: Amoxicillin/clavulanate (Augmentin) If penicillin allergic: fluoroquinolone plus clindamycin Alternative: Third-generation cephalosporin plus anaerobic coverage with clindamycin or metronidazole (Flagyl) Note: quinolones not indicated in children |
|
|
|
|
Suspected MRSA–CA |
|
Suspected based on clinical appearance and relative frequency of MRSA-CA seen in one’s community |
IV: Vancomycin or clindamycin Oral: Trimethoprim/sulfamethoxazole (Bactrim), clindamycin |
|
|
|
|
Suspected MRSA–HA |
|
|
IV: Vancomycin or linezolid or daptomycin |
|
|
|
|
Necrotizing fasciitis |
Streptococcus or Polymicrobial |
Treat both until organism is identified |
Broad-spectrum beta-lactam (piperacillin/tazobactam; imipenem) plus vancomycin (for MRSA) plus clindamycin (for synergy for Streptococcus pyogenes) |
|
|
|
|
Gas in soft tissues |
Clostridium perfringens (gas gangrene) Polymicrobial infections (anaerobic and facultative anaerobes) |
IVDA and diabetics more often have polymicrobial infections—often gas in the soft tissues |
High-dose penicillin plus clindamycin Broad-spectrum beta-lactam (piperacillin/tazobactam; imipenem) plus vancomycin (for MRSA) plus clindamycin (for synergy for S. pyogenes) |
|
|
|
|
IVDA, Intravenous drug abusers; MRSA, methicillin-resistant Staphylococcus aureus; MRSA-CA, community-acquired MRSA; MRSA-HA, hospital-acquired MRSA. |